← Leaderboards
Roberto Claudio Arduino
University Of Texas Hlth Sci Ctr Houston
$6,562,247
Attributed
$8,287,267
Total exposure
6
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $725.4K · FY2005–22$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$8,287,267 · 6
By mechanism
U01$4,826,098 · 1
R01$3,450,041 · 1
M01$11,128 · 4
Top collaborators
- Claudio Soto5 shared
Most similar at University Of Texas Hlth Sci Ctr Houston
Same institution · by research overlap
- Rodrigo Morales$8,127,531
- Jocelyne H Bachevalier$13,246,208
- Bhanu Priya Ganesh$3,101,267
- Mohammad Shahnawaz$1,472,760
- Sandra Pritzkow$1,045,010
Others in their field
Top investigators on “Drug Screening /Evaluation”
- Fred M Gordin · Social And Scientific Systems, Inc.$68,001,399
- John C S Breitner · Johns Hopkins University$33,065,187
- Philip J Disaia · University Of California Irvine$21,551,991
- George R Painter · Chimerix, Inc.$19,230,662
- Gregory H Reaman · National Childhood Cancer Foundation$17,052,970
- Stephen J Durako · Westat, Inc.$15,048,684
Research focus
Drug Screening /EvaluationClinical ResearchHiv InfectionsHuman SubjectHuman Therapy EvaluationAids TherapyAntiaids AgentPharmacokineticsAlzheimer&AposClinical Trial Phase IDrug Adverse EffectCommunityAntibodiesAmyloid StructureAmyloid Beta-ProteinAidsAcquired Immunodeficiency SyndromeAgedBiologicalBiochemicalBiological ModelsBloodBrainAmyloid
Grant awards (24)
Misfolded Protein Aggregates in HIV infection$685,591
R01 · FY2022 · AG
Misfolded Protein Aggregates in HIV infection$685,830
R01 · FY2021 · AG
Misfolded Protein Aggregates in HIV infection$689,684
R01 · FY2020 · AG
Misfolded Protein Aggregates in HIV infection$689,915
R01 · FY2019 · AG
Misfolded Protein Aggregates in HIV infection$699,021
R01 · FY2018 · AG
HOUSTON AIDS RESEARCH TEAM (HART)$482,402
U01 · FY2006 · AI · contact PI
HOUSTON AIDS RESEARCH TEAM (HART)$725,412
U01 · FY2005 · AI
HOUSTON AIDS RESEARCH TEAM (HART)$725,412
U01 · FY2004 · AI
HOUSTON AIDS RESEARCH TEAM (HART)$725,412
U01 · FY2003 · AI
HOUSTON AIDS RESEARCH TEAM (HART)$719,022
U01 · FY2002 · AI
Safety, tolerance, pharmacokinetics, &antiviral activity of DAPD in HIV infectio$0
M01 · FY2002 · RR
T 20 ADMINISTERED TO HIV 1+ ADULTS BY SUBCUTANEOUS INFUSION OR INJECTION$0
M01 · FY2002 · RR
Phase II trial for HIV infected adults with prior T-20 treatement$0
M01 · FY2002 · RR
Phase I trial to evaluate safety, pharmacokinetics, &antiviral activity of T-124$0
M01 · FY2002 · RR
HOUSTON AIDS RESEARCH TEAM (HART)$786,545
U01 · FY2001 · AI
Phase I trial to evaluate safety, pharmacokinetics, &antiviral activity of T-124$0
M01 · FY2001 · RR
Safety, tolerance, pharmacokinetics, &antiviral activity of DAPD in HIV infectio$0
M01 · FY2001 · RR
Phase II trial for HIV infected adults with prior T-20 treatement$0
M01 · FY2001 · RR
T 20 ADMINISTERED TO HIV 1+ ADULTS BY SUBCUTANEOUS INFUSION OR INJECTION$0
M01 · FY2001 · RR
HOUSTON AIDS RESEARCH TEAM (HART)$661,893
U01 · FY2000 · AI
T 20 ADMINISTERED TO HIV 1+ ADULTS BY SUBCUTANEOUS INFUSION OR INJECTION$11,128
M01 · FY2000 · RR
Phase I trial to evaluate safety, pharmacokinetics, &antiviral activity of T-124$0
M01 · FY2000 · RR
Safety, tolerance, pharmacokinetics, &antiviral activity of DAPD in HIV infectio$0
M01 · FY2000 · RR
Phase II trial for HIV infected adults with prior T-20 treatement$0
M01 · FY2000 · RR